Friday, July 1, 2016

Long term outcomes data presented on efficacy of Soliris in aHUS

At the ASN's Kidney Week being held in Philadelphia, USA, researchers presented data from clinical trials of Soliris (Eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), as well as an update from the Global aHUS Registry.

Data was presented for a wide variety of patients including children and adults and both transplanted and non-transplanted patients.

This is very important because Soliris, being a new drug, not much is known about its long term implications. Such ongoing studies will really help to understand how it helps to maintain kidney function for long durations, an extremely important factor for aHUS patients.

More details can be found here.

No comments:

Post a Comment